Centiva Capital’s AN2 Therapeutics ANTX Stock Holding History

Centiva Capital’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-75,000	Closed	-$257K	–	1811
2026 Q1	$257K	Buy	+75,000	New	+$155K	﹤0.01%	1129

Other funds holding ANTX

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Centiva Capital's ANTX Position: Q2 2026 in Review

Centiva Capital sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 75,000 shares — an estimated $257K sold.

Centiva Capital first reported a position in ANTX in Q1 2026 and held it in 1 quarter. The position peaked at $257K in Q1 2026. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

Centiva Capital reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
Centiva Capital sold 75,000 AN2 Therapeutics shares in Q2 2026, an estimated $257K.
Centiva Capital first reported a position in AN2 Therapeutics in Q1 2026 and held it in 1 quarter.
Centiva Capital's AN2 Therapeutics position peaked at $257K in Q1 2026.
66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.